Skip to main content
SpringerLink
Log in

Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acutely ill males

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Summary

The pharmacokinetics of ceftazidime have been investigated after single and multiple i.v. doses in 9 young healthy male volunteers and 15 elderly male patients with acute bacterial infections. All subjects had normal, age-correlated glomerular function.

Distribution and elimination in young volunteers were unaffected by posture and were similar to what has been reported earlier. In contrast, elderly patients had longer t1/2β (3.1 vs 1.9 h), larger AUC (414.0 vs 276.6 h·mg/l), lower total and renal clearances, reduced urinary recovery over 12 h and enlarged Vss. Total serum clearance of ceftazidime was closely correlated with the51Cr-EDTA clearance. There was no significant change in51Cr-EDTA clearance after seven days of treatment.

A reduction in the dose of betalactam antibiotics eliminated by the kidney is advisable in elderly patients with an acute bacterial infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Greenblatt DJ, Sellers EM, Shader RI (1982) Drug disposition in old age. N Engl J Med 306: 1081–1088

    Google Scholar 

  2. Ljungberg B, Nilsson-Ehle I (1987) Pharmacokinetics of antimicrobial agents in the elderly. Rev Infect Dis 9: 250–264

    Google Scholar 

  3. O'Callaghan CH, Acred P, Harper PB, Ryan DM, Kirby SM, Harding SM (1980) GR 20263, a new broad-spectrum cephalosporin with antipseudomonal activity. Antimicrob Agents Chemother 17: 876–883

    Google Scholar 

  4. Höffler D, Koeppe P, Williams KJ (1983) The pharmacokinetics of ceftazidime in normal and impaired renal function. J Antimicrob Chemother 12 [Suppl A]: 241–245

    Google Scholar 

  5. Ryan DM, Cars O (1983) A problem in the interpretation of betalactam antibiotic levels in tissues. J Antimicrob Chemother 12: 281–284

    Google Scholar 

  6. Harding SM (1982) Clinical pharmacology of ceftazidime. In: Periti F, Grassi GG (eds) Current chemotherapy and immunotherapy: Proceedings of the 12th International Congress of Chemotherapy, Florence, Italy, July 1981. American Society for Microbiology, Washington, DC, pp 495–498

    Google Scholar 

  7. Lüthy R, Blaser J, Bonetti A, Simmen H, Wise R, Siegenthaler W (1981) Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother 20: 567–575

    Google Scholar 

  8. Ljungberg B, Nilsson-Ehle I (1988) Influence of age on the pharmacokinetics of ceftazidime in acutely ill, adult patients. Eur J Clin Pharmacol 34: 173–178

    Google Scholar 

  9. Broechner-Mortensen J (1972) A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 30: 271–274

    Google Scholar 

  10. Granerus G, Aurell M (1981) Reference values for51Cr-EDTA clearance as a measure of glomerular filtration rate. Scand J Clin Lab Invest 41: 611–616

    Google Scholar 

  11. Ayrton J (1981) Assay of ceftazidime in biological fluids using high-pressure liquid chromatography. J Antimicrob Chemother 8 [Suppl B]: 227–231

    Google Scholar 

  12. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York, pp 413–414

    Google Scholar 

  13. Davies DF, Shock NW (1950) Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest 29: 496–507

    Google Scholar 

  14. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW (1976) The effect of age on creatinine clearance in men: A cross-sectional and longitudinal study. J Gerontol 31: 155–163

    Google Scholar 

  15. Ackerman BH, Ross J, Tofte RW, Rotschafer JC (1984) Effect of decreased renal function on the pharmacokinetics of ceftazidime. Antimicrob Agents Chemother 25: 785–786

    Google Scholar 

  16. Alestig K, Trollfors B, Andersson R, Olaison L, Suurküla M, Norrby SR (1984) Ceftazidime and renal function. J Antimicrob Chemother 13: 177–181

    Google Scholar 

  17. Gower PE, Hobbs PM, Harding SM (1982) Kinetics of ceftazidime in renal impairment. In: Periti P, Grassi GG (eds) Current chemotherapy and immunotherapy: Proceedings of the 12th International Congress of Chemotherapy, Florence, Italy, July 1981. American Society for Microbiology, Washington DC, pp 498–499

    Google Scholar 

  18. Leroy A, Leguy F, Borsa F, Spencer GR, Fillastre JP, Humbert G (1984) Pharmacokinetics of ceftazidime in normal and uremic subjects. Antimicrob Agents Chemother 25: 638–642

    Google Scholar 

  19. Norrby SR, Burman LÅ, Linderholm H, Trollfors B (1982) Ceftazidime: Pharmacokinetics in patients and effects on the renal function. J Antimicrob Chemother 10: 199–206

    Google Scholar 

  20. Welage LS, Schultz RW, Schentag JJ (1984) Pharmacokinetics of ceftazidime in patients with renal insufficiency. Antimicrob Agents Chemother 25: 201–204

    Google Scholar 

  21. Drusano GL, Joshi J, Forrest A, Ruxer R, Standiford H, Leslie J, Wade J, Schimpff S (1985) Pharmacokinetics of ceftazidime, alone or in combination with piperacillin or tobramycin, in the sera of cancer patients.Antimicrob Agents Chemother 27: 605–607

    Google Scholar 

  22. Narang PK, Hunter JR (1984) Is renal function the only determinant in the elimination of ceftazidime? Rev Infect Dis 6: 732–735

    Google Scholar 

  23. Ljungberg B, Nilsson-Ehle I (1984) Pharmacokinetics of ceftazidime in elderly patients and young volunteers. Scand J Infect Dis 16: 325–326

    Google Scholar 

  24. LeBel M, Barbeau G, Vallée F, Bergeron MG (1985) Pharmacokinetics of ceftazidime in elderly volunteers. Antimicrob Agents Chemother 28: 713–715

    Google Scholar 

  25. Naber KG, Kees F, Grobecker H (1983) Ceftazidime: Pharmacokinetics in young volunteers versus elderly patients and therapeutic efficacy with complicated urinary tract infections. J Antimicrob Chemother 12 [Suppl A]: 41–45

    Google Scholar 

  26. Acred P, Harding SM, Ryan DM (1981) The in vivo properties of GR 20263 (ceftazidime) — a highly active broad-spectrum cephalosporin with anti-pseudomonal activity. Drugs Exp Clin Res 7: 189–199

    Google Scholar 

  27. Armstrong GC, Wise R, Brown RM, Hancox J (1981) Comparison of ceftazidime and cefamandole pharmacokinetics and blister fluid concentrations. Antimicrob Agents Chemother 20: 356–358

    Google Scholar 

  28. Drusano GL, Standiford HC, Fitzpatrick B, Leslie J, Tangtatsawasdi P, Ryan P, Tatem B, Moody MR, Schimpff SC (1984) Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers. Antimicrob Agents Chemother 26: 388–393

    Google Scholar 

  29. Harding SM, Monro AJ, Thornton JE, Ayrton J, Hogg MIJ (1981) The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers. J Antimicrob Chemother 8 [Suppl B]: 263–272

    Google Scholar 

  30. Kemmerich B, Warns H, Lode H, Borner K, Koeppe P, Knothe H (1983) Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. Antimicrob Agents Chemother 24: 333–338

    Google Scholar 

  31. Tjandramaga TB, Van Hecken A, Mullie A, Verbesselt R, DeSchepper PJ, Verbist L (1982) Comparative pharmacokinetics of ceftazidime and moxalactam. Antimicrob Agents Chemother 22: 237–241

    Google Scholar 

  32. Ogilvie RI (1983) An introduction to pharmacokinetics. J Chron Dis 36: 121–127

    Google Scholar 

  33. Bruce Å, Andersson M, Arvidsson B, Isaksson B (1980) Body composition. Prediction of normal body potassium, body water and body fat in adults on the basis of body height, body weight and age. Scand J Clin Lab Invest 40: 461–473

    Google Scholar 

  34. Shock NW, Watkin DM, Yiengst MJ, Norris AH, Gaffney GW, Gregerman RI, Falzone JA (1963) Age differences in the water content of the body as related to basal oxygen consumption in males. J Gerontol 18: 1–8

    Google Scholar 

  35. Andritz MH, Smith RP, Baltch AL, Griffin PE, Conroy JV, Sutphen N, Hammer MC (1984) Pharmacokinetics of moxalactam in elderly subjects. Antimicrob Agents Chemother 25: 33–36

    Google Scholar 

  36. Cutler NR, Narang PK, Lesko LJ, Ninos M, Power M (1984) Vancomycin disposition: The importance of age. Clin Pharmacol Ther 36: 803–810

    Google Scholar 

  37. Wilson K (1984) Sex-related differences in drug disposition in man. Clin Pharmacokinet 9: 189–202

    Google Scholar 

  38. Sommers DK, Walters L, Van Wyk M, Harding SM, Paton AM, Ayrton J (1983) Pharmacokinetics of ceftazidime in male and female volunteers. Antimicrob Agents Chemother 23: 892–896

    Google Scholar 

  39. Wittmann DH, Schassan HH, Kohler F, Seibert W (1981) Pharmacokinetic studies of ceftazidime in serum, bone, bile, tissue fluid and peritoneal fluid. J Antimicrob Chemother 8 [Suppl B]: 293–297

    Google Scholar 

  40. Ganzinger U, Haslberger A (1985) Pharmacokinetics of cephalosporins in normal and septicemic rabbits. Antimicrob Agents Chemother 28: 473–477

    Google Scholar 

  41. Ganzinger U, Haslberger A, Schiel H, Omilian-Rosso R, Schütze E (1986) Influence of endotoxin on the distribution of cephalosporins in rabbits. J Antimicrob Chemother 17: 785–793

    Google Scholar 

  42. Goldblum SE, Reed WP (1983) Effect of intravascular pneumococcal challenge on vascular permeability in rabbits. J Infect Dis 148: 179

    Google Scholar 

  43. Pennington JE, Dale DC, Reynolds HY, MacLowry JD (1975) Gentamicin sulfate pharmacokinetics: Lower levels of gentamicin in blood during fever. J Infect Dis 132: 270–275

    Google Scholar 

  44. Landahl S, Aurell M, Jagenburg R (1981) Glomerular filtration rate at the age of 70 and 75. J Clin Exp Gerontol 3: 29–45

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, University of Lund, Lund, Sweden

    B. Ljungberg & I. Nilsson-Ehle

Authors
  1. B. Ljungberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Nilsson-Ehle
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ljungberg, B., Nilsson-Ehle, I. Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acutely ill males. Eur J Clin Pharmacol 34, 179–186 (1988). https://doi.org/10.1007/BF00614556

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00614556

Key words

Search

Navigation